Navigation Links
Chromos enters into loan and lending arrangements
Date:3/20/2008

BURNABY, BC, March 20 /PRNewswire-FirstCall/ - Chromos Molecular Systems Inc. ("Chromos") (TSX:CHR) announced today that the Company entered into a secured, convertible debenture agreement to borrow $400,000. The proceeds of the loan are to be used to fund expenses associated with the preparation of delinquent continuous disclosure documents and maintaining the integrity of the remaining assets of the Company. The principal and interest, at 12% per annum, are due and payable on June 30, 2008. The debenture holder has the right, upon notice, to convert all or part of the principal and unpaid interest into common shares of the Company at the conversion price of $0.03 per share. The Company also entered into a Pledge of Securities agreement as part of the security arrangement with the debenture holder for the Company's common shares in Agrisoma Biosciences Inc. ("Agrisoma"). As collateral for the convertible debenture, the Company provided the debenture holder a general security agreement providing a charge over all the Company's assets. Prior to entering into this transaction, the Company obtained a partial revocation of the existing cease trade order from the B.C. Securities Commission.

The Company has also entered into a convertible promissory note agreement (the "Agrisoma Note") to loan $500,000 to Agrisoma. Of this amount, $118,000 was funded in-kind by Chromos by offsetting it against $118,000 of amounts due from Agrisoma for license fees, rent and other services, and patent cost recoveries. The remaining $382,000 was funded in cash by Chromos to Agrisoma. The cash advanced to Agrisoma is to be used for operations. The secured Agrisoma Note, which bears interest of 15% per annum, is due the earlier of: June 30, 2008 and certain specified events. As collateral for the Agrisoma Note, Agrisoma provided the Company with a general security agreement providing a charge over all of Agrisoma's assets.

Risks and Uncertainties

Certain of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Chromos, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

To the extent possible, management implements strategies to reduce or mitigate the risks and uncertainties associated with Chromos' operations. Operating risks include (i) the continued availability of capital to finance Chromos' activities; (ii) Chromos' limited cash position, and (iii) Chromos' limited operations.

CONTACT: Jeff Charpentier, Vice President, Finance and CFO, Tel: (604) 415-7132, Email:jcharpentier@chromos.com; Alistair Duncan, President & CEO, Tel: (604) 415-7121, Email: aduncan@chromos.com, Website: http://www.chromos.com


'/>"/>
SOURCE Chromos Molecular Systems Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
2. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
3. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
4. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
5. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
6. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
7. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
8. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
9. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
10. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
11. Sangui Partnership Enters a New Phase:
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):